Key statistics dashboard for Innate Pharma S.A. (IPHA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections.
Stock Data
| Price | $2.01 |
| Market Cap | $189M |
| Enterprise Value | $139.8M |
| Beta | 0.74 |
| Exchange | NASDAQ |
| Country | FR |
Valuation Multiples
| P/E Ratio | -2.84 |
| Price / Book | -6.57 |
| P/S | 52.56 |
| EV/EBITDA | -2.50 |
| EV/Sales | 50.18 |
| EV/FCF | -2.64 |
| P/FCF | -2.77 |
| Earnings Yield | -34.75% |
| FCF Yield | -36.39% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -2058.02% |
| EBITDA Margin | -2008.36% |
| Operating Margin | -2058.02% |
| Net Margin | -1764.51% |
| Return on Equity | 593.93% |
| Return on Assets | -78.41% |
| Return on Invested Capital | -155.52% |
| Return on Capital Employed | -220.01% |
Financial Health
| Current Ratio | 1.27 |
| Quick Ratio | 1.27 |
| Cash Ratio | 0.77 |
| Debt / Equity | -1.04 |
| Debt / Assets | 35.99% |
| Net Debt / EBITDA | 0.10 |
| Interest Coverage | -18.38 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -11.35 |
Per-Share Data
| Revenue per share | 0.03 |
| Book Value per share | -0.24 |
| Cash per share | 0.38 |
| FCF per share | -0.58 |
| Tangible Book Value per share | -0.24 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.67 |
Related companies: APLT · CGEN · CRBP · CRDF · CYBN · ELTX · MIST
Explore sector: Healthcare · Biotechnology
More sections of IPHA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks